title: Binding by immunoglobulin to the HPV-16-derived proteins L1 and E4 in cervical secretions of women with HPV-related cervical disease.
abstract: Although DNA of the human papillomaviruses (HPV) can be identified in epithelium of a large proportion of patients with genital squamous lesions, relatively little is known about the extent of the local host immune response to this virus. We analyzed cervical secretions from patients undergoing evaluation because of abnormal Papanicolaou smears (cervical biopsy showed nonspecific atypia, flat condyloma, or intraepithelial neoplasia), as well as controls, for immunoglobulin binding to proteins produced in vitro to HPV-16 L1, E4, and E7 open reading frames. Segments of the HPV-16 genome, including portions of the L1 (nucleotides 6153-6794), E4 (nucleotides 3399-3648), and E7 (nucleotides 686-880) open reading frames, were cloned into pATH vectors and expressed as tryptophan synthetase E fusion proteins in Escherichia coli and used as a source of study antigens. Fusion proteins containing the HPV L1, E4, and E7 polypeptides were found to be distinct by molecular weight (59,000; 45,000; and 42,000) as well as by immunological determinants recognized by heterologous immune sera. Of 8 cervical intraepithelial neoplasia lesions tested by RNA-RNA in situ hybridization, 7 were found to be positive for HPV-16-related nucleic acids, in contrast to none (0 of 4) in the condyloma group (three positive for HPV DNA other than type 16). Immunoglobulin in cervical secretions showed reactivity to HPV type 16 E4 or L1 or both, with highest binding in patients with cervical intraepithelial neoplasia (P less than 0.01 for HPV-16 L1 and E4 compared with controls). Binding was not tryptophan synthetase E dependent and was, in general, coincident for the HPV-16 E4 and L1 proteins. We conclude that study of cervical secretions, using a quantitative assay for immunoglobulin binding to HPV-16 proteins produced in vitro, may be useful to document the quality and quantity of the immune response of the host to this important human pathogen.
authors.affiliation: Department of Pathology, University of Virginia Health Sciences Center, Charlottesville 22908.
authors.forename: K A
authors.initials: KA
authors.lastname: Snyder
authors.forename: S R
authors.initials: SR
authors.lastname: Barber
authors.forename: M
authors.initials: M
authors.lastname: Symbula
authors.forename: P T
authors.initials: PT
authors.lastname: Taylor
authors.forename: C P
authors.initials: CP
authors.lastname: Crum
authors.forename: J K
authors.initials: JK
authors.lastname: Roche
mesh_terms: D000936:Antigen-Antibody Complex; D036022:Capsid Proteins; D002584:Cervix Uteri / Q000378:metabolism / Q000382:microbiology*; D005260:Female; D005814:Genes, Viral; D006801:Humans; D015151:Immunoblotting; D007136:Immunoglobulins; D009856:Oncogene Proteins, Viral / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D016366:Open Reading Frames; D027383:Papillomaviridae / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification; D011993:Recombinant Fusion Proteins / Q000032:analysis / Q000276:immunology; D014412:Tumor Virus Infections / Q000382:microbiology* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000382:microbiology* / Q000473:pathology
chemical_list: D000936:Antigen-Antibody Complex; D036022:Capsid Proteins; D007136:Immunoglobulins; D009856:Oncogene Proteins, Viral; D011993:Recombinant Fusion Proteins; C069119:oncogene protein E4, Human papillomavirus type 16; C063317:L1 protein, Human papillomavirus type 16